Dlk1 is a novel adrenocortical stem/progenitor cell marker that predicts malignancy in adrenocortical carcinoma

Katia Mariniello; James F. H. Pittaway; Barbara Altieri; Kleiton Silva Borges; Irene Hadjidemetriou; Claudio Ribeiro; Gerard Ruiz-Babot; David S. Tourigny; Jiang A. Lim; Julie Foster; Julie Cleaver; Jane Sosabowski; Nafis Rahman; Milena Doroszko; Constanze Hantel; Sandra Sigala; Andrea Abate; Mariangela Tamburello; Katja Kiseljak-Vassiliades; Margaret Wierman; Charlotte Hall; Laila Parvanta; Tarek E. Abdel-Aziz; Teng-Teng Chung; Aimee Di Marco; Fausto Palazzo; Celso E. Gomez-Sanchez; David R. Taylor; Oliver Rayner; Cristina L. Ronchi; Carles Gaston-Massuet; Silviu Sbiera; William M. Drake; Emanuel Rognoni; Matthias Kroiss; David T. Breault; Martin Fassnacht; Leonardo Guasti

doi:10.1002/cac2.70012

Cancer Communications ›› 2025, Vol. 45 ›› Issue (6) : 663 -668. DOI: 10.1002/cac2.70012

LETTER TO THE JOURNAL

Dlk1 is a novel adrenocortical stem/progenitor cell marker that predicts malignancy in adrenocortical carcinoma

Author information +

¹. Centre for Endocrinology, William Harvey Research Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK

². Division of Endocrinology and Diabetes, Dept. of Medicine, University Hospital, University of Würzburg, Würzburg, Germany

³. Division of Endocrinology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA

⁴. Harvard Stem Cell Institute, Cambridge, Massachusetts, USA

⁵. Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technical, University Dresden, Dresden, Germany

⁶. School of Mathematics, University of Birmingham, Birmingham, UK

⁷. Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London, UK

⁸. Institute of Biomedicine, University of Turku, Turku, Finland

⁹. Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich (USZ) and University of Zurich (UZH), Zurich, Switzerland

¹⁰. Section of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy

¹¹. Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA

¹². Division of Endocrinology, Metabolism and Diabetes at Rocky Mountain Regional Veterans Affair Medical Center, Washington, District of Columbia, USA

¹³. Department of Surgery, St Bartholomew's Hospital, West Smithfield, London, UK

¹⁴. Department of Surgery, University College London Hospitals NHS Foundation Trust, London, UK

¹⁵. Department of Endocrinology, University College London Hospitals NHS Foundation Trust, London, UK

¹⁶. Department of Endocrine and Thyroid Surgery, Hammersmith Hospital, Imperial College London, London, UK

¹⁷. Endocrine Section, G.V. (Sonny) Montgomery VA Medical Center and the Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, Mississippi, USA

¹⁸. Department of Clinical Biochemistry (Synnovis Analytics), King's College Hospital, London, UK

¹⁹. Institute of Metabolism and System Research College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK

²⁰. Centre for Cell Biology & Cutaneous Research, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK

²¹. Department of Internal Medicine IV, LMU University Hospital, LMU Munich, München, Germany

j.pittaway@qmul.ac.uk

Show less

History +

PDF

Cite this article

Download citation ▾

Katia Mariniello, James F. H. Pittaway, Barbara Altieri, Kleiton Silva Borges, Irene Hadjidemetriou, Claudio Ribeiro, Gerard Ruiz-Babot, David S. Tourigny, Jiang A. Lim, Julie Foster, Julie Cleaver, Jane Sosabowski, Nafis Rahman, Milena Doroszko, Constanze Hantel, Sandra Sigala, Andrea Abate, Mariangela Tamburello, Katja Kiseljak-Vassiliades, Margaret Wierman, Charlotte Hall, Laila Parvanta, Tarek E. Abdel-Aziz, Teng-Teng Chung, Aimee Di Marco, Fausto Palazzo, Celso E. Gomez-Sanchez, David R. Taylor, Oliver Rayner, Cristina L. Ronchi, Carles Gaston-Massuet, Silviu Sbiera, William M. Drake, Emanuel Rognoni, Matthias Kroiss, David T. Breault, Martin Fassnacht, Leonardo Guasti. Dlk1 is a novel adrenocortical stem/progenitor cell marker that predicts malignancy in adrenocortical carcinoma. Cancer Communications, 2025, 45(6): 663-668 DOI:10.1002/cac2.70012

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]

Fassnacht M, Dekkers OM, Else T, Baudin E, Berruti A, de Krijger R, et al. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2018; 179(4): G1-G46.

[2]	Pittaway JFH, Guasti L. Pathobiology and genetics of adrenocortical carcinoma. J Mol Endocrinol. 2019; 62(2): R105-R19.

[3]	Guasti L, Cavlan D, Cogger K, Banu Z, Shakur A, Latif S, et al. Dlk1 up-regulates Gli1 expression in male rat adrenal capsule cells through the activation of beta1 integrin and ERK1/2. Endocrinology. 2013; 154(12): 4675-84.

[4]	Hadjidemetriou I, Mariniello K, Ruiz-Babot G, Pittaway J, Mancini A, Mariannis D, et al. DLK1/PREF1 marks a novel cell population in the human adrenal cortex. J Steroid Biochem Mol Biol. 2019; 193: 105422.

[5]	Pittaway JFH, Lipsos C, Mariniello K, Guasti L. The role of delta-like non-canonical Notch ligand 1 (DLK1) in cancer. Endocr Relat Cancer. 2021; 28(12): R271-R87.

[6]	Basham KJ, Hung HA, Lerario AM, Hammer GD. Mouse models of adrenocortical tumors. Mol Cell Endocrinol. 2016; 421: 82-97.

[7]	Mathieu M, Drelon C, Rodriguez S, Tabbal H, Septier A, Damon-Soubeyrand C, et al. Steroidogenic differentiation and PKA signaling are programmed by histone methyltransferase EZH2 in the adrenal cortex. Proc Natl Acad Sci U S A. 2018; 115(52): E12265-E74.

[8]	Borges KS, Pignatti E, Leng S, Kariyawasam D, Ruiz-Babot G, Ramalho FS, et al. Wnt/beta-catenin activation cooperates with loss of p53 to cause adrenocortical carcinoma in mice. Oncogene. 2020; 39(30): 5282-91.

[9]	Warde KM, Smith LJ, Liu L, Stubben CJ, Lohman BK, Willett PW, et al. Senescence-induced immune remodeling facilitates metastatic adrenal cancer in a sex-dimorphic manner. Nat Aging. 2023; 3(7): 846-65.

[10]	Mohan DR, Borges KS, Finco I, LaPensee CR, Rege J, Solon AL, et al. beta-Catenin-Driven Differentiation Is a Tissue-Specific Epigenetic Vulnerability in Adrenal Cancer. Cancer Res. 2023; 83(13): 2123-41.